Health
NAFDAC raises the alarm over fake Paludex drugs, uncovers counterfeit hub in Aba
- /home/naijuinz/public_html/wp-content/plugins/mvp-social-buttons/mvp-social-buttons.php on line 27
https://naijablitznews.com/wp-content/uploads/2024/07/NAFDAC.jpg&description=NAFDAC raises the alarm over fake Paludex drugs, uncovers counterfeit hub in Aba', 'pinterestShare', 'width=750,height=350'); return false;" title="Pin This Post">
- Share
- Tweet /home/naijuinz/public_html/wp-content/plugins/mvp-social-buttons/mvp-social-buttons.php on line 72
https://naijablitznews.com/wp-content/uploads/2024/07/NAFDAC.jpg&description=NAFDAC raises the alarm over fake Paludex drugs, uncovers counterfeit hub in Aba', 'pinterestShare', 'width=750,height=350'); return false;" title="Pin This Post">
NAFDAC has warned Nigerians about the sale and distribution of fake Paludex tablets and suspensions across the country.
The agency announced on its X account (formerly Twitter) that fake Paludex Artemether/Lumefantrine tablets (80mg/480mg) were falsely labelled as being made by Impact Pharmaceutical Ltd, located at Standard Industrial Layout, Emene, Enugu State.
It added that these fake drugs are being distributed by MD Life Sciences Ltd, also based in Emene Industrial Layout, Enugu.
NAFDAC further revealed the discovery of counterfeit Paludex dry powder for oral suspension (180mg/1080mg), meant for children.
NAFDAC stated that the counterfeit Paludex oral suspension was falsely labelled as being manufactured by Impact Pharmaceutical Ltd, located at No. 33A/33B Standard Industrial Layout, Enugu, and Ecomed Pharma Limited in Ogun State, and marketed by MD Life Sciences Ltd.
The agency revealed that laboratory tests conducted by a WHO-prequalified laboratory in Germany showed that both products contained zero per cent of the Active Pharmaceutical Ingredients (API). Additional tests conducted by NAFDAC also confirmed the absence of any API in the products.
The statement further disclosed that the fake products are not listed in NAFDAC’s database of registered drugs, and the NAFDAC registration numbers displayed on the packaging are fake.
NAFDAC emphasized that authentic Artemether/Lumefantrine tablets or suspensions are a combination of two active ingredients, Artemether and Lumefantrine, used for treating acute, uncomplicated malaria in both adults and children.
“The illegal marketing of medicines or counterfeit medicines poses a great risk to the health of people.
“By not complying with the regulatory provisions, the safety, quality, and efficacy of the products are not guaranteed.
“Also, poor-quality pediatric formulations or medicines in general have the potential of causing treatment failure when the API content is below the prescribed dose,” it said.
NAFDAC said that all its zonal directors and state coordinators have been directed to carry out surveillance and mop up the fake products within their zones and states.
It also implored distributors, healthcare providers, and patients to exercise caution and vigilance within the supply chain to avoid distribution, administration, and use of the products.
The agency said that all medical products must be obtained from authorised/licensed suppliers.
“The products’ authenticity and physical condition should be carefully checked.
“Anyone in possession of any of the above-mentioned products is advised to immediately discontinue the sale or use and submit stock to the nearest NAFDAC office.
The agency advised the public, especially those who have used any of the products to seek immediate medical advice from a qualified healthcare professional.
It also advised healthcare professionals and consumers to report any suspicion of substandard and falsified medicines to the nearest NAFDAC office, NAFDAC on 0800-162-3322 or via email: [email protected].
In another development, NAFDAC also identified Eziukwu Market, also known as Cemetery Market in Aba, Abia State, as a major hub for producing and distributing fake and substandard products.
This discovery followed an operation led by NAFDAC’s South-East Zonal Director, Martins Iluyomade, on Tuesday.
During the operation, Iluyomade described the market as a centre for large-scale production and distribution of counterfeit goods, comparing its impact to “weapons of mass destruction.” Despite earlier raids, including a major one in December 2023, the illegal activities have persisted.
Iluyomade expressed frustration that people continue to prioritize profits over public health and safety. He also pointed out that the market leaders had previously signed an agreement with NAFDAC during the last operation, promising to expose those involved in these illegal activities.
However, he stressed that the market’s leadership must now answer serious questions about their failure to stop the production and sale of fake products.
Health
NAFDAC Blacklists Onifam Laboratories, Directors Over Regulatory Infractions
The National Agency for Food and Drug Administration and Control (NAFDAC) has blacklisted Onifam Laboratories Limited, its Managing Director/Chief Executive Officer, all members of its board of directors, and every affiliated or associated individual and entity found to have participated in regulatory violations, following what it described as extensive investigations into the company’s operations.
The sanction, which takes immediate effect, effectively excludes the company and all affected individuals from participating in any pharmaceutical business regulated by NAFDAC pending further directive from the agency.
In a statement signed on Monday by its Director-General/CEO, Prof. Mojisola Adeyeye, the agency said its investigations established that Onifam Laboratories engaged in regulatory misrepresentation, misuse of NAFDAC approvals and certificates, improper registration and transfer of pharmaceutical products, as well as activities that deliberately circumvented established regulatory procedures.
According to NAFDAC, the alleged infractions compromise product traceability, weaken accountability within the pharmaceutical supply chain and expose the public to significant health risks.
The agency said the company’s actions violate the provisions of the NAFDAC Act, the Food, Drug and Related Products (Registration, etc.) Act, the Drug and Related Products Registration Regulations 2021 and other applicable regulatory guidelines governing pharmaceutical products in Nigeria.
As part of the blacklist, Onifam Laboratories and all affected persons are prohibited from participating, either directly or indirectly, in any pharmaceutical business regulated by NAFDAC.
The prohibition extends to applying for or benefiting from any NAFDAC registration, licence, permit, certificate or approval.
It also bars them from operating as manufacturers, importers, distributors, marketing authorisation holders, agents, representatives, consultants, promoters or sponsors of any product regulated by the agency.
Prof. Mojisola Adeyeye, Director-General/Chief Executive Officer of the National Agency for Food and Drug Administration and Control (NAFDAC), whose agency announced the immediate blacklisting of Onifam Laboratories Ltd, its Managing Director, directors and affiliated entities over multiple regulatory violations/Credit: NAFDAC
The sweeping sanctions equally apply to affiliated companies and associated entities found to have been involved in the regulatory violations.
NAFDAC stated that the blacklist would remain in force until otherwise directed by its management.
The agency further warned that it reserves the right to initiate additional regulatory, administrative, enforcement and legal actions where necessary to protect public health and preserve the integrity of Nigeria’s medicines regulatory system.
It stressed that the action reflects its determination to ensure strict compliance with pharmaceutical regulations and deter practices capable of undermining the safety and quality of medicines available to Nigerians.
Reaffirming its commitment to safeguarding public health, NAFDAC urged all stakeholders in the pharmaceutical sector to comply fully with applicable laws and regulatory requirements.
The agency maintained that only safe, quality-assured and properly regulated medicines should be manufactured, imported, distributed and sold in Nigeria, warning that any attempt to bypass regulatory procedures would attract decisive sanctions.
The blacklist of Onifam Laboratories marks one of the agency’s strongest recent enforcement actions and underscores its resolve to strengthen regulatory oversight, improve accountability within the pharmaceutical industry and sustain public confidence in Nigeria’s medicines regulatory framework.
Health
What is being released to NCDC is a drop in the ocean- Senate C’ttee laments
Poor funding could undermine the ability of the North Central Development Commission (NCDC) to deliver on its mandate, the Senate has said, insisting that the N2.9 billion monthly allocation being released to the commission is only “a drop in the ocean” compared to its N140 billion budget allocation for 2026.
The Chairman of the Senate Committee on the North Central Development Commission, Titus Zam, sounded the warning while briefing journalists after an interactive session between the committee and the commission’s management at the National Assembly on Tuesday.
According to him, the current monthly release would amount to less than half of the commission’s approved budget if maintained throughout the year, expressing optimism that the federal government would increase funding as the commission becomes fully operational.
“If you give someone that has a budget of N140 billion, N2.9 billion per month, in 12 months, it won’t be up to half of the entire budgetary sum,” Zam said.
“I suppose that is just a temporary package. When the commission finally comes to fruition, much more funds will be released. So we thank Mr President and the Executive for dropping something now, but we look forward to more.”
The lawmaker, however, assured that the Senate Committee would ensure the prudent utilisation of the funds already released by providing effective oversight and guiding the commission on areas of priority.
He urged the commission to focus its interventions on agriculture, security and rural development, stressing that the North Central region is largely agrarian and continues to face serious security challenges.
“North Central is mostly an agricultural land. We have arable land, we have good rainfall and vegetation. There is policy for agriculture. We need the department of NCDC to take agriculture very seriously.
“We also have a challenge of insecurity. The commission is advised to support the security forces and state governments to complement their efforts towards mitigating the tide of insecurity within the region.
“We also ask them to take rural development very seriously because we are also rural in nature,” Zam said.
Health
NCDC records rise in Lassa fever cases, death toll hits 221
The Nigeria Centre for Disease Control and Prevention (NCDC) says Nigeria recorded an increase in confirmed Lassa fever cases during epidemiological week 26 of 2026, with 31 new infections reported, up from 22 the previous week.
The new confirmed cases were recorded in Bauchi, Ondo, Taraba and Benue states, according to the latest NCDC Lassa fever situation report released by the public health agency on Friday.
The report showed that 221 deaths have been recorded cumulatively in 2026, with a Case Fatality Rate (CFR) of 24.0 per cent, higher than the 18.7 per cent reported in 2025.
It stated that 23 states had reported at least one confirmed Lassa fever case across 111 Local Government Areas, indicating the continued geographic spread of the disease nationwide in 2026.
According to the report, 85 per cent of all confirmed cases originated from Ondo, Bauchi, Taraba, Edo and Benue states, while the remaining 15 per cent were reported elsewhere.
The report said Ondo accounted for the highest proportion of confirmed cases at 30 per cent, followed by Bauchi with 26 per cent, Taraba with 14 per cent, Edo with nine per cent, and Benue.
It revealed that people aged between 21 and 30 years remained the most affected group, although confirmed cases ranged from one to 93 years, with a median age.
The report also showed that the male-to-female ratio among confirmed cases stood at 1:0.9, suggesting nearly equal infection rates between males and females across affected states.
Health authorities noted that both suspected and confirmed Lassa fever cases increased compared with the corresponding period in 2025, while one healthcare worker was infected during week 26.
The report added that the National Lassa Fever multi-partner, multi-sectoral Incident Management System remains activated to coordinate surveillance, case management, risk communication and response activities nationwide.
-
News20 hours agoUS Slams Killing of Rev. Ezekiel Dachomo’s Family in Plateau, Demands Justice
-
News15 hours ago‘Defected govs believe presidency will write results’ – Kwankwaso on why Govs joined APC
-
News22 hours agoPhoto News: Proud father, FCT minister, Wike hosts friends to dinner in celebration of daughter’s graduation
-
News16 hours agoJust in: Bangladesh President Mohammed Shahabuddin Quits Office
-
News16 hours agoDangote: MRS Filling Stations Shut For Seven Days
-
News16 hours ago2027: Two federal lawmakers resign from APC join PDP
-
News23 hours agoI have treated 15 patients – Suspected fake doctor claims
-
News23 hours agoNBA: I’ll quit if evidence of election rigging emerges – Badejo-Okusanya

Warning: Undefined variable $user_ID in /home/naijuinz/public_html/wp-content/themes/zox-news/comments.php on line 49
You must be logged in to post a comment Login